Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Immune Responses Raised in an Experimental Colon Carcinoma Model Following Oral Administration of Lactobacillus casei.

Aindelis G, Tiptiri-Kourpeti A, Lampri E, Spyridopoulou K, Lamprianidou E, Kotsianidis I, Ypsilantis P, Pappa A, Chlichlia K.

Cancers (Basel). 2020 Feb 5;12(2). pii: E368. doi: 10.3390/cancers12020368.

2.

Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry.

Diamantopoulos PT, Pappa V, Symeonidis A, Kotsianidis I, Galanopoulos A, Papadaki H, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Kotsopoulou M, Repousis P, Dimou M, Solomou E, Pontikoglou C, Kyriakakis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Panayiotidis P, Viniou NA.

Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):114-121. doi: 10.1016/j.clml.2019.09.614. Epub 2019 Sep 28.

PMID:
31884152
3.

Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.

Kazachenka A, Young GR, Attig J, Kordella C, Lamprianidou E, Zoulia E, Vrachiolias G, Papoutselis M, Bernard E, Papaemmanuil E, Kotsianidis I, Kassiotis G.

Genome Med. 2019 Dec 23;11(1):86. doi: 10.1186/s13073-019-0707-x.

4.

Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.

Ng KW, Attig J, Young GR, Ottina E, Papamichos SI, Kotsianidis I, Kassiotis G.

Elife. 2019 Nov 15;8. pii: e50256. doi: 10.7554/eLife.50256.

5.

The STAT signaling profile at the single cell level reveals novel insights in the association of FOXP3+ T regulatory cells with recurrent spontaneous abortions before and after lymphocyte immunotherapy.

Lamprianidou E, Daniilidis M, Kordella C, Zoulia E, Nakou E, Gerofotis A, Vasilaki A, Pantos G, Kotsianidis I.

Clin Immunol. 2020 Jan;210:108261. doi: 10.1016/j.clim.2019.108261. Epub 2019 Nov 2.

PMID:
31689518
6.

Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma.

Petrakis I, Kontogiorgis C, Nena E, Athanasakis K, Gougoula V, Kotsianidis I, Constantinidis TC.

Expert Rev Hematol. 2019 Dec;12(12):1063-1075. doi: 10.1080/17474086.2019.1668763. Epub 2019 Sep 24.

PMID:
31524011
7.

Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group.

Papageorgiou SG, Kontos CK, Kotsianidis I, Karousi P, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V.

J Geriatr Oncol. 2020 Jan;11(1):121-124. doi: 10.1016/j.jgo.2019.07.018. Epub 2019 Jul 27. No abstract available.

PMID:
31362867
8.

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).

Kotsianidis I, Papageorgiou SG, Pappa V, Galanopoulos AG, Viniou NA, Vassilakopoulos TP, Papoutselis M, Vrachiolias G, Papadopoulos V, Diamantopoulos PT, Tsokanas D, Kourakli A, Symeonidis A.

Mediterr J Hematol Infect Dis. 2019 Jul 1;11(1):e2019045. doi: 10.4084/MJHID.2019.045. eCollection 2019. No abstract available.

9.

Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.

Lamprianidou E, Zoulia E, Bernard E, Kordella C, Papoutselis M, Bezirgiannidou Z, Vrachiolias G, Papaemmanuil E, Kotsianidis I.

Leuk Lymphoma. 2019 Dec;60(13):3277-3281. doi: 10.1080/10428194.2019.1627542. Epub 2019 Jun 12. No abstract available.

PMID:
31185765
10.

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Cermâk J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Simec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants.

Haematologica. 2020 Mar;105(3):632-639. doi: 10.3324/haematol.2018.212217. Epub 2019 Jun 6.

11.

Immunoporosis: A New Role for Invariant Natural Killer T (NKT) Cells Through Overexpression of Nuclear Factor-κB Ligand (RANKL).

Tilkeridis K, Kiziridis G, Ververidis A, Papoutselis M, Kotsianidis I, Kitsikidou G, Tousiaki NE, Drosos G, Kapetanou A, Rechova KV, Kazakos K, Spanoudakis E.

Med Sci Monit. 2019 Mar 23;25:2151-2158. doi: 10.12659/MSM.912119.

12.

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.

Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, Galanopoulos A, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, Hatzimichael E, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsonis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group.

Cancer Med. 2019 May;8(5):2056-2063. doi: 10.1002/cam4.2090. Epub 2019 Mar 21.

13.

Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.

Diamantopoulos PT, Kontandreopoulou CN, Symeonidis A, Kotsianidis I, Pappa V, Galanopoulos A, Vassilakopoulos T, Dimou M, Solomou E, Kyrtsonis MC, Siakantaris M, Angelopoulou M, Kourakli A, Papageorgiou S, Christopoulou G, Roumelioti M, Panayiotidis P, Viniou NA; Hellenic MDS Study Group.

Ann Hematol. 2019 Jun;98(6):1383-1392. doi: 10.1007/s00277-019-03650-w. Epub 2019 Mar 15.

PMID:
30877373
14.

Isothiocyanate-induced Cell Cycle Arrest in a Novel In Vitro Exposure Protocol of Human Malignant Melanoma (A375) Cells.

Mantso T, Anestopoulos I, Lamprianidou E, Kotsianidis I, Pappa A, Panayiotidis MI.

Anticancer Res. 2019 Feb;39(2):591-596. doi: 10.21873/anticanres.13152.

PMID:
30711934
15.

Detection of CALR Mutations Using High Resolution Melting Curve Analysis (HRM-A); Application on a Large Cohort of Greek ET and MF Patients.

Giannopoulos A, Rougkala N, Loupis T, Mantzourani M, Viniou NA, Variami E, Vassilakopoulos TP, Dryllis G, Kotsianidis I, Gougopoulou T, Politou M, Konstantopoulos K, Vassilopoulos G.

Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019009. doi: 10.4084/MJHID.2019.009. eCollection 2019.

16.

Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath?

Papalexandri A, Karypidou M, Stalika E, Kotta K, Touloumenidou T, Zerva P, Paleta A, Mallouri D, Batsis I, Sakellari I, Kotsianidis I, Anagnostopoulos A, Hadzidimitriou A, Margaritis D, Stamatopoulos K.

Leuk Lymphoma. 2019 Jul;60(7):1685-1692. doi: 10.1080/10428194.2018.1543881. Epub 2019 Jan 17.

PMID:
30652530
17.

Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.

Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Gogos D, Karakatsanis S, Papadaki H, Palla A, Hatzimichael E, Dimou M, Papageorgiou S, Delimpasis S, Papaioannou M, Papoutselis M, Kourakli A, Tsokanas D, Anagnostopoulos A, Kontos CK, Panayiotidis P, Viniou NA; Hellenic MDS study group.

Leuk Lymphoma. 2019 Jul;60(7):1721-1730. doi: 10.1080/10428194.2018.1540783. Epub 2018 Nov 14.

PMID:
30424699
18.

The JAK2V617F Point Mutation Increases the Osteoclast Forming Ability of Monocytes in Patients with Chronic Myeloproliferative Neoplasms and Makes their Osteoclasts more Susceptible to JAK2 Inhibition.

Spanoudakis E, Papoutselis M, Bazdiara I, Lamprianidi E, Kordella X, Tilkeridis C, Tsatalas C, Kotsianidis I.

Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018058. doi: 10.4084/MJHID.2018.058. eCollection 2018.

19.

Lactobacillus paracasei K5 displays adhesion, anti-proliferative activity and apoptotic effects in human colon cancer cells.

Chondrou P, Karapetsas A, Kiousi DE, Tsela D, Tiptiri-Kourpeti A, Anestopoulos I, Kotsianidis I, Bezirtzoglou E, Pappa A, Galanis A.

Benef Microbes. 2018 Dec 7;9(6):975-983. doi: 10.3920/BM2017.0183. Epub 2018 Oct 24.

PMID:
30353740
20.

The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.

Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V.

Hematol Oncol. 2018 Oct;36(4):693-700. doi: 10.1002/hon.2551. Epub 2018 Sep 7.

PMID:
30129144
21.

Improving the Subcutaneous Mouse Tumor Model by Effective Manipulation of Magnetic Nanoparticles-Treated Implanted Cancer Cells.

Spyridopoulou K, Aindelis G, Lampri E, Giorgalli M, Lamprianidou E, Kotsianidis I, Tsingotjidou A, Pappa A, Kalogirou O, Chlichlia K.

Ann Biomed Eng. 2018 Dec;46(12):1975-1987. doi: 10.1007/s10439-018-2107-6. Epub 2018 Aug 3.

PMID:
30076502
22.

Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.

Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, Galanopoulos A, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V.

Leuk Res. 2018 Aug;71:55-59. doi: 10.1016/j.leukres.2018.07.004. Epub 2018 Jul 7. No abstract available.

PMID:
30007218
23.

Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.

Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M.

Hematol Oncol. 2018 Oct;36(4):645-650. doi: 10.1002/hon.2521. Epub 2018 Jun 8.

PMID:
29882363
24.

Eluate testing with monospecific antisera unmasks multiple immunoglobulin classes and identifies frequent IgA involvement in severe autoimmune hemolytic anemia.

Bezirgiannidou Z, Kontekaki E, Christoforidou A, Zisaki S, Chouchos K, Papamichos S, Vrachiolias G, Papoutselis M, Spanoudakis E, Martinis G, Kotsianidis I, Mantadakis E.

Transfus Apher Sci. 2018 Jun;57(3):384-387. doi: 10.1016/j.transci.2018.04.020. Epub 2018 Apr 22. No abstract available.

PMID:
29716828
25.

The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.

Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V.

Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16.

26.

Myeloid Neoplasms with Isolated Isochromosome 17q: a yet to be Defined Entity.

Lamprianidou E, Kordella C, Papoutselis M, Bezyrgiannidou Z, Nakou E, Papamichos S, Spanoudakis E, Giannopoulos A, Zoi K, Kotsianidis I.

Mediterr J Hematol Infect Dis. 2017 Nov 1;9(1):e2017066. doi: 10.4084/MJHID.2017.066. eCollection 2017.

27.

Potentially probiotic Lactobacillus strains with anti-proliferative activity induce cytokine/chemokine production and neutrophil recruitment in mice.

Saxami G, Karapetsas A, Chondrou P, Vasiliadis S, Lamprianidou E, Kotsianidis I, Ypsilantis P, Botaitis S, Simopoulos C, Galanis A.

Benef Microbes. 2017 Aug 24;8(4):615-623. doi: 10.3920/BM2016.0202. Epub 2017 Jun 16.

PMID:
28618861
28.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.

J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

PMID:
28350519
29.

Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.

Diamantopoulos P, Zervakis K, Zervakis P, Sofotasiou M, Vassilakopoulos T, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Solomou E, Kodandreopoulou E, Papadopoulou V, Korkolopoulou P, Mantzourani M, Kyriakakis G, Viniou NA.

Blood Cancer J. 2017 Feb 17;7(2):e533. doi: 10.1038/bcj.2016.127.

30.

Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.

Spanoudakis E, Papoutselis M, Terpos E, Dimopoulos MA, Tsatalas C, Margaritis D, Rahemtulla A, Kotsianidis I, Karadimitris A.

Blood Cancer J. 2016 Nov 11;6(11):e500. doi: 10.1038/bcj.2016.108. No abstract available.

31.

A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.

Pappa V, Anagnostopoulos A, Bouronikou E, Briasoulis E, Kotsianidis I, Pagoni M, Zikos P, Tsionos K, Viniou N, Meletis J, Papadaki H, Kioumi A, Galanopoulos A, Vervessou EC, Poulakidas E, Karmas P, Karvounis K, Symeonidis A.

Int J Hematol. 2017 Feb;105(2):184-195. doi: 10.1007/s12185-016-2115-y. Epub 2016 Nov 4.

PMID:
27815858
32.

Gradient Infiltration of Neutrophil Extracellular Traps in Colon Cancer and Evidence for Their Involvement in Tumour Growth.

Arelaki S, Arampatzioglou A, Kambas K, Papagoras C, Miltiades P, Angelidou I, Mitsios A, Kotsianidis I, Skendros P, Sivridis E, Maroulakou I, Giatromanolaki A, Ritis K.

PLoS One. 2016 May 2;11(5):e0154484. doi: 10.1371/journal.pone.0154484. eCollection 2016.

33.

Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition.

Skendros P, Papagoras C, Lefaki I, Giatromanolaki A, Kotsianidis I, Speletas M, Bocly V, Theodorou I, Dalla V, Ritis K.

Br J Dermatol. 2017 Jan;176(1):212-215. doi: 10.1111/bjd.14685. Epub 2016 Oct 12.

PMID:
27105586
34.

Lactobacillus casei Exerts Anti-Proliferative Effects Accompanied by Apoptotic Cell Death and Up-Regulation of TRAIL in Colon Carcinoma Cells.

Tiptiri-Kourpeti A, Spyridopoulou K, Santarmaki V, Aindelis G, Tompoulidou E, Lamprianidou EE, Saxami G, Ypsilantis P, Lampri ES, Simopoulos C, Kotsianidis I, Galanis A, Kourkoutas Y, Dimitrellou D, Chlichlia K.

PLoS One. 2016 Feb 5;11(2):e0147960. doi: 10.1371/journal.pone.0147960. eCollection 2016.

35.

The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.

Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Kontos CK, Adamopoulos PG, Nakou E, Vakalopoulou S, Garypidou V, Papaioannou M, Hatjiharissi E, Papadaki HA, Spanoudakis E, Pappa V, Scorilas A, Tsatalas C, Kotsianidis I; Hellenic MDS Study Group.

Clin Cancer Res. 2016 Apr 15;22(8):1958-68. doi: 10.1158/1078-0432.CCR-15-1288. Epub 2015 Dec 23.

37.

Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia.

Papadopoulou V, Kontandreopoulou E, Panayiotidis P, Roumelioti M, Angelopoulou M, Kyriazopoulou L, Diamantopoulos PT, Vaiopoulos G, Variami E, Kotsianidis I, Athina Viniou N.

Leuk Lymphoma. 2016 May;57(5):1182-8. doi: 10.3109/10428194.2015.1090573. Epub 2015 Dec 23.

PMID:
26373709
38.

Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms.

Miltiades P, Lamprianidou E, Kerzeli IK, Nakou E, Papamichos SI, Spanoudakis E, Kotsianidis I.

Leuk Res. 2015 Aug 14. pii: S0145-2126(15)30357-X. doi: 10.1016/j.leukres.2015.08.004. [Epub ahead of print]

PMID:
26307524
39.

PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.

Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki H, Dimopoulos MA, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I, Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P.

Leukemia. 2016 Jan;30(1):238-42. doi: 10.1038/leu.2015.120. Epub 2015 May 14. No abstract available.

PMID:
25971363
40.

Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study.

Oriol A, Giraldo P, Kotsianidis I, Couturier C, Olie R, Angermund R, Corso A.

Hematology. 2015 Aug;20(7):405-9. doi: 10.1179/1607845414Y.0000000218. Epub 2014 Dec 10.

PMID:
25494809
41.

Sequential development of different acute leukemia types in the same patient.

Kotsianidis I, Tsatalas C.

Blood. 2014 Oct 16;124(16):2608. No abstract available.

PMID:
25485345
42.

Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients.

Fouka E, Lamprianidou E, Arvanitidis K, Filidou E, Kolios G, Miltiades P, Paraskakis E, Antoniadis A, Kotsianidis I, Bouros D.

Lung. 2014 Dec;192(6):849-55. doi: 10.1007/s00408-014-9619-0. Epub 2014 Jul 14.

PMID:
25016929
43.

Surface antigen expression in CLL: a new member among the mnesteres for the prognosis of bad risk disease.

Kotsianidis I.

Leuk Res. 2014 Apr;38(4):423-4. doi: 10.1016/j.leukres.2014.01.011. Epub 2014 Jan 30. No abstract available.

PMID:
24636703
44.

Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway.

Pavlaki K, Pontikoglou CG, Demetriadou A, Batsali AK, Damianaki A, Simantirakis E, Kontakis M, Galanopoulos A, Kotsianidis I, Kastrinaki MC, Papadaki HA.

Stem Cells Dev. 2014 Jul 15;23(14):1568-81. doi: 10.1089/scd.2013.0283. Epub 2014 Apr 21.

PMID:
24617415
45.

Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine.

Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Pappa V, Papadaki HA, Spanoudakis E, Tsatalas K, Kotsianidis I.

Blood Cancer J. 2014 Feb 28;4:e187. doi: 10.1038/bcj.2014.9. No abstract available.

46.

Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience.

Papoutselis M, Douvali E, Papadopoulos V, Spanoudakis E, Margaritis D, Tsatalas C, Kotsianidis I.

Leuk Res. 2014 Feb;38(2):161-5. doi: 10.1016/j.leukres.2013.10.015. Epub 2013 Oct 28.

PMID:
24239174
47.

Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.

Douvali E, Papoutselis M, Vassilakopoulos TP, Papadopoulos V, Spanoudakis E, Tsatalas C, Kotsianidis I.

Leuk Res. 2013 Aug;37(8):889-93. doi: 10.1016/j.leukres.2013.05.005. Epub 2013 May 29.

PMID:
23726719
48.

CD1d expression as a prognostic marker for chronic lymphocytic leukemia.

Anastasiadis A, Kotsianidis I, Papadopoulos V, Spanoudakis E, Margaritis D, Christoforidou A, Gouliamtzi S, Tsatalas C.

Leuk Lymphoma. 2014 Feb;55(2):320-5. doi: 10.3109/10428194.2013.803222. Epub 2013 Jul 8.

PMID:
23668820
49.

Synchronous BALT Lymphoma and Squamous Cell Carcinoma of the Lung: Coincidence or Linkage?

Oikonomou A, Astrinakis E, Kotsianidis I, Kaloutsi V, Didilis V, Tsatalas K, Prassopoulos P.

Case Rep Oncol Med. 2013;2013:420393. doi: 10.1155/2013/420393. Epub 2013 Feb 28.

50.

Epidural anesthesia followed by epidural analgesia produces less inflammatory response than spinal anesthesia followed by intravenous morphine analgesia in patients with total knee arthroplasty.

Chloropoulou P, Iatrou C, Vogiatzaki T, Kotsianidis I, Trypsianis G, Tsigalou C, Paschalidou E, Kazakos K, Touloupidis S, Simopoulos K.

Med Sci Monit. 2013 Jan 28;19:73-80.

Supplemental Content

Loading ...
Support Center